SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Solid Biosciences Inc.

NEW YORK--()--Levi & Korsinsky announces it has commenced an investigation of Solid Biosciences Inc. (NASDAQGS:SLDB) concerning possible violations of federal securities laws.

On March 14, 2018, Solid Biosciences issued a press release announcing receipt of a “notification from the U.S. Food and Drug Administration that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.” Upon this news, shares of Solid Biosciences were down more than 63% on intraday trading on March 15, 2018. To obtain additional information, go to:

http://www.zlkdocs.com/SLDB-Info-Request-Form-6535

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky announces it has commenced an investigation of Solid Biosciences Inc.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com